Currently out of the existing stock ratings of Mathew Blackman, 34 are a HOLD (34.69%), 64 are a BUY (65.31%).

Mathew Blackman

Work Performance Price Targets & Ratings Chart

Analyst Mathew Blackman, currently employed at STIFEL, carries an average stock price target met ratio of 60.82% that have a potential upside of 28.75% achieved within 127 days.

Mathew Blackman’s has documented 211 price targets and ratings displayed on 17 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on CLPT, Clearpoint Neuro at 01-Apr-2025.

Wall Street Analyst Mathew Blackman

Analyst best performing recommendations are on ELGX (ENDOLOGIX).
The best stock recommendation documented was for CLPT (CLEARPOINT NEURO) at 8/8/2024. The price target of $10 was fulfilled within 7 days with a profit of $0.94 (10.38%) receiving and performance score of 14.82.

Average potential price target upside

of $18.24 (20.75%) on DXCM (DEXCOM).
of $16.94 (6.76%) on PODD (INSULET).
of $13.02 (17.83%) on INGN (INOGEN).

AHCO Adapthealth Corp ATEC Alphatec Holdings CERS Cerus DXCM DexCom GMED Globus Medical NUVA NuVasive OFIX Orthofix Medical SENS Senseonics Holdings SPNE SeaSpine Holdings Corp CSII Cardiovascular Systems ELGX Endologix INGN Inogen APEN Apollo Endosurgery PODD Insulet TNDM Tandem Diabetes Care WMGI Wright Medical Group N.V CLPT Clearpoint Neuro

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

David Macdonald (TRUIST)